SQ-LIP-000025 · v1.3 (archived) · View current version →
What specific genetic variants or inheritance patterns have been identified in lipedema?
Also asked as
- Which particular gene mutations or hereditary patterns have been linked to lipedema?
- Is lipedema inherited, and what specific genetic variants are known to be involved?
- lipedema genetic variants inheritance pattern identified
- What genes and modes of inheritance have researchers found associated with lipedema?
Based on currently indexed evidence, no single gene or definitive Mendelian inheritance pattern has been confirmed for primary non-syndromic lipedema; the data consistently point to a polygenic/oligogenic complex trait with genetic heterogeneity. Familial clustering is well documented, with positive family history reported in roughly 15% to 89% of cases across studies (≈14.9% of probands with an affected first-degree relative in one series of 67 probands; up to 64–89% in reviews). The most frequently proposed mode is autosomal dominant inheritance with incomplete penetrance and sex limitation (female-preferential); X-linked dominant transmission was explicitly excluded by X-chromosome linkage analysis in the largest studied family (Li05; lod scores below -2), favoring autosomal dominant with sex limitation (moderate grade). Genome-wide association studies of UK Biobank women (24,450; European ancestry) identified 18 genome-wide significant loci (a polygenic signal), with VEGFA and GRB14-COBLL1 (plus ADAMTS9, LYPLAL1) replicating directionally in an independent clinically diagnosed cohort, and RSPO3 among the lead signals (moderate-grade cross-sectional GWAS); a smaller UK cohort GWAS (n=130) reported a suggestive (not genome-wide significant) signal at rs1409440 near LHFPL6 (OR_meta 2.01, P 4×10⁻⁶; low grade), and a 2022 GWAS in 130 carriers reported regions near CPE, ZNF25, and ZNF33A (estrogen biology). Family-based exome sequencing of 9 families (31 individuals, moderate grade) found candidate variants across 469 genes with no single shared gene, enriched in vasopressin receptor activity (AVPR1A, AVPR2), microfibril binding (FBN, ELN, LTBP), and Hedgehog/patched (PTCH1/2) pathways. A targeted 305-gene NGS panel in 162 patients (low-to-moderate grade) found heterozygous deleterious variants in 17 patients (~10.5%; 21 variants) across 12 genes involved in steroidogenesis, lipid homeostasis, and insulin signaling (PLIN1, LIPE, ALDH18A1, PPARG, GHR, INSR, RYR1, NPC1, POMC, NR0B2, GCKR, PPARA; PLIN1 c.722T>C is linked to familial partial lipodystrophy type 4). AKR1C-family genes have emerged as a recurrent candidate locus, supported by a familial AKR1C1 p.Leu213Gln (L213Q) missense variant segregating across three generations (reducing catalytic efficiency ~50% in progesterone metabolism), additional missense variants (L54V, L54F, N280K) predicted to disrupt substrate/cofactor (NADP+) binding, an AKR1C2 gain-of-function variant (Ser320PheTer2) and AKR1C2 overexpression in ~24% of mutation-negative patients, and regulatory SNPs (rs28571848 at a glucocorticoid-receptor site, rs34477787 at an RORα site); however, these derive from low-grade reviews, basic-science/computational work, and single families. Lower-grade or single-source findings also include a familial PIT1/POU1F1 mutation, altered expression of ZNF423, CAV1, CCND1, CYP19A1 (aromatase), COL6A3, and MMP14, and an IL-6 rs1800795 (-174G/C) G-allele association (OR=5.92) from a single small case-control study. Syndromic forms with overlapping fat phenotypes have defined mutations (e.g., POU1F1A c.196C>T p.Pro24Leu, NSD1/Sotos p.Cys2175Ser, 7q11.23/Williams-Beuren involving ELN/FZD9/MLXIPL, ABCC6/PXE, ALDH18A1/cutis laxa). Reviews emphasize no overlap with primary lymphedema or classic lipodystrophy genes, and that genetic studies overall remain underpowered.
⚙ AI consolidation: Claude Opus 4.8 · openrouter · 2026-05-31 — evidence-bounded; the AI does not opine
Knowledge freshness = share of the 17 indexed evidence sources from the last 5 years (newest 2026, oldest 2010) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
supporting contradicting refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
What changed in this version
Answer recompiled after human curation of the claim set.
Supporting claims
- SCR-LIP-000214 supporting
In a case-control study using TaqMan genotyping, carriers of the IL-6 rs1800795 (-174G/C) G allele (CG+GG) had a 5.92-fold higher risk of lipedema versus non-carriers (CC) (OR=5.92, 95%CI 1.983–17.711, p<0.001), with samples in Hardy-Weinberg equilibrium.
DOI:10.26355/eurrev_202003_20690 - SCR-LIP-000216 supporting
A 305-gene NGS panel applied to 162 lipedema patients identified 21 heterozygous deleterious variants in 17 patients (10.5%) across 12 genes (PLIN1, LIPE, PPARG, POMC, NR0B2, GCKR, NPC1, ALDH18A1, GHR, INSR, RYR1, PPARA), most involved in steroidogenesis, lipid homeostasis, and insulin signaling, including PLIN1 c.722T>C linked to familial partial lipodystrophy type 4.
A Multi-Gene Panel to Identify Lipedema-Predisposing Genetic Variants by a Next-Generation Sequencing Strategy — Michelini et al. (2022) · Lipedema: Progress, Challenges, and the Road Ahead — Cifarelli (2025) - SCR-LIP-000217 supporting
This systematic review reports specific genetic findings in lipedema including an AKR1C1 missense variant (Michelini 2020) associated with reduced progesterone clearance and increased adipogenesis, a familial Pit1 mutation causing GH and testosterone deficiency (Bano 2010), and upregulation of ZNF423 and CAV1 dysfunction, supporting a possible genetic susceptibility component.
Impact of hormones on lipedema development: a systematic literature review — Lüchinger et al. (2026) · Lipedema Research—Quo Vadis? — Ernst et al. (2023) - SCR-LIP-000233 supporting
In a series of 67 probands, 14.9% had a first-degree relative with confirmed lipedema and X-chromosome linkage analysis in the largest family (Li05) returned lod scores below -2, excluding X-linked dominant inheritance and favoring autosomal dominant inheritance with sex limitation.
Lipedema: An inherited condition — Child et al. (2010) - SCR-LIP-000235 supporting
This review reports lipedema as polygenic with familial history in 30-89% of cases, citing a 2022 GWAS (130 carriers) identifying 6 regions (CPE, ZNF25, ZNF33A linked to estrogen biology), a UK Biobank study (24,450 women) finding 18 loci replicating VEGFA and GRB14-COBLL1, a partial loss-of-function missense variant in AKR1C1 in a non-syndromic lipedema family, and a multigene panel of 305 loci finding 17 probable deleterious lesions in 21/162 participants, with no single causal gene and no overlap with primary lymphedema or lipodystrophies.
Unraveling lipedema: comprehensive insights and the path to future discoveries — Faria et al. (2025) · Genome-wide association study of a lipedema phenotype among women in the UK Biobank identifies multiple genetic risk factors — Klimentidis et al. (2023) - SCR-LIP-000236 supporting
A GWAS of a UK lipedema cohort (n=130) identified a suggestive association (not genome-wide significant) at SNP rs1409440 (OR_meta 2.01; P_meta 4×10⁻⁶) located upstream of LHFPL6, a gene involved in lipoma formation, with additional support from an independent 100,000 Genomes replication cohort.
Investigation of clinical characteristics and genome associations in the ‘UK Lipoedema’ cohort — Grigoriadis et al. (2022) - SCR-LIP-000238 supporting
This systematic review reports that lipedema most likely follows autosomal dominant inheritance with incomplete penetrance and sex limitation (positive family history in up to 64% of women), identifies no confirmed gene for primary non-syndromic lipedema, and catalogs syndromic associations (POU1F1A c.196C>T p.Pro24Leu; NSD1 p.Cys2175Ser/Sotos; 7q11.23 deletion/Williams-Beuren with ELN, FZD9, MLXIPL; ABCC6/PXE; ALDH18A1/cutis laxa III) plus 17 GWAS/animal-model candidate genes (e.g., LYPLAL1, TBX15, HOXC13, RSPO3, VEGFA, PROX1, VEGFR3, PRDM16).
DOI:10.26355/eurrev_201907_18292 - SCR-LIP-000239 supporting
This narrative review reports that lipedema follows a female-preferential autosomal dominant inheritance pattern and is associated with altered expression of specific genes including CCND1, ZNF423, CYP19A1 (aromatase), COL6A3, and MMP14, while noting that genetic studies remain underpowered.
Lipedema: Insights into Morphology, Pathophysiology, and Challenges — Poojari et al. (2022) - SCR-LIP-000240 supporting
This review identifies specific lipedema-associated variants in AKR1C genes, including the familial AKR1C1 p.Leu213Gln (L213Q) mutation segregating across three generations and reducing catalytic efficiency ~50%, the gain-of-function AKR1C2 Ser320PheTer2 mutation, AKR1C2 overexpression in 24% (5/21) of patients without coding mutations, and regulatory SNPs rs28571848 (glucocorticoid receptor site) and rs34477787 (RORα site) that increase AKR1C2/AKR1C3 expression and truncal fat mass independent of BMI.
From rare familial mutations to multifactorial disease: aldo-keto reductase 1C enzymes as a central biological pathway in lipedema — Vainberg et al. (2026) - SCR-LIP-000241 supporting
Targeted NGS and molecular dynamics simulations identified three missense AKR1C1 variants (L54V, L54F, N280K) in lipedema patients that disrupt substrate or cofactor (NADP+) binding, and screening of gnomAD identified 8 rare AKR1C1 polymorphisms as potentially pathogenic, extending AKR1C1 as a candidate gene for autosomal dominant non-syndromic lipedema.
DOI:10.26355/eurrev_202312_34698
Contradictory claims
- None indexed yet.
Refining / context
- SCR-LIP-000215 refines
Family-based exome sequencing of 31 individuals from 9 lipedema families identified candidate variants in 469 genes with no single gene shared across all families, supporting genetic heterogeneity rather than a Mendelian single-gene cause, with gene ontology enrichment in vasopressin receptor activity (AVPR1A, AVPR2), microfibril binding (FBN, ELN, LTBP), and patched binding (PTCH1/2, Hedgehog pathway).
A Family-Based Study of Inherited Genetic Risk in Lipedema — Morgan et al. (2024) - SCR-LIP-000218 context
A systematic review of lipedema pathology reported that, despite growing histological and molecular research, the aetiology remains largely uncertain; it noted differential gene expression in lipedema adipose-derived stem cells (3429 genes, including cell-cycle genes Bub1, CDC20, BIRC5 per Ishaq) but did not identify specific inherited variants or defined inheritance patterns.
Auf der Suche nach der Evidenz: Eine systematische Übersichtsarbeit zur Pathologie des Lipödems — Funke et al. (2023) - SCR-LIP-000234 context
This narrative review describes lipedema as having a hereditary component with familial inheritance and notes shared and distinct genetic markers between lipedema and lymphedema, but the abstract is truncated before specifying particular genetic variants or inheritance patterns.
Current Mechanistic Understandings of Lymphedema and Lipedema: Tales of Fluid, Fat, and Fibrosis — Duhon et al. (2022) - SCR-LIP-000237 context
This review cites whole-exome sequencing (Michelini et al., 2020) associating lipedema with variants in sex-hormone-related genes involved in subcutaneous fat deposition, and proposes that dysregulated estrogen receptor (ERα/ERβ) signaling and local adipose estrogen production contribute to lipedema pathophysiology.
Lipedema and the Potential Role of Estrogen in Excessive Adipose Tissue Accumulation — Katzer et al. (2021)
Major uncertainty
No causal gene or definitive inheritance pattern is established for primary non-syndromic lipedema. The strongest available evidence is moderate at best (a UK Biobank GWAS using an inferred rather than clinically diagnosed phenotype, and family-based exome sequencing in small samples); nearly all variant-level findings (AKR1C1/AKR1C2, IL-6, candidate-gene panel hits) come from single families, small case series, computational predictions, or narrative reviews and lack independent replication in adequately powered, clinically diagnosed cohorts. Whether the proposed autosomal-dominant/sex-limited model or a polygenic/oligogenic model best describes inheritance remains unresolved, and the relative contribution of any individual candidate gene is unquantified.
Version history
- SQ-LIP-000025 · v1.3 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000025 · v1.2 — 2026-05-31 — This update strengthened the moderate-grade GWAS basis (UK Biobank 18 loci with VEGFA/GRB14-COBLL1/ADAMTS9/LYPLAL1/RSPO3 and ~5.13% SNP heritability), explicitly added X-linked dominant exclusion via linkage favoring autosomal dominant with sex limitation, expanded the AKR1C-family candidate evidence (familial AKR1C1 L213Q across three generations plus L54V/L54F/N280K and AKR1C2 variants/regulatory SNPs), and catalogued syndromic gene associations and additional candidate/expression genes. · view this version
- SQ-LIP-000025 · v1.1 — 2026-05-31 — This update established the first indexed answer, compiling moderate-grade family-based exome and NGS-panel evidence for genetic heterogeneity (469-gene and 12-gene candidate sets), reported familial occurrence with proposed X-linked/autosomal dominant incomplete-penetrance inheritance, and registered specific lower-grade candidate findings (AKR1C1, Pit1, ZNF423, CAV1, IL-6 rs1800795). · view this version
- SQ-LIP-000025 · v1.0 — 2026-05-31 — Question created (promoted from SQ-LIP-D000008). · view this version
Key references
DOI:10.26355/eurrev_202003_20690 · DOI:10.1089/lrb.2023.0065 · DOI:10.3390/jpm12020268 · DOI:10.1111/obr.13953 · DOI:10.1007/s00404-026-08318-1 · DOI:10.3390/jpm13010098 · DOI:10.1055/a-2183-7414 · DOI:10.1002/ajmg.a.33313 · DOI:10.3390/ijms23126621 · DOI:10.1038/s44324-025-00093-y · DOI:10.1038/s41431-022-01231-6 · DOI:10.1371/journal.pone.0274867 · DOI:10.3390/ijms222111720 · DOI:10.26355/eurrev_201907_18292 · DOI:10.3390/biomedicines10123081 · DOI:10.4081/vl.2026.15495 · DOI:10.26355/eurrev_202312_34698